Financial Information
This section of the Karyopharm Therapeutics InvestorRoom houses up to date financial reporting information and interactive tools to provide you with the resources you need to manipulate and understand our current financial standing.
Please note: All data in this section is provided by a 3rd party provider and may be delayed up to 20 minutes. Karyopharm Therapeutics assumes no responsibility for the accuracy of this data and provides it for informational purposes only.
NASDAQKPTI
| Beta | (0.17) |
|---|---|
| Shares Outstanding | 79.4M |
| Average Volume (10 days) | 3.0M |
| Qtrly Dividend (Ann. Yield) | -- (--) |
Analyst Views
| Current Mean Recommendation | Buy |
|---|
| Strong Buy | 2 | |
|---|---|---|
| Buy | 0 | |
| Hold | 5 | |
| Underperform | 0 | |
| Sell | 0 |
Recent Insider Transactions
Richard Paulson Director, President and CEO | (633) Sell May 4, 2022 |
|---|---|
Richard Paulson Director, President and CEO | (27,869) Sell May 4, 2022 |
Sharon Shacham President & CSO | 60,000 Acquire Mar 29, 2022 |
Sharon Shacham Chief Scientific Officer | 60,000 Acquire Mar 29, 2022 |
Michael Glen Kauffman Director | (6,226) Sell Feb 28, 2022 |